How GlaxoSmithKline plc Fits Into Your Portfolio

Despite Berkshire Hathaway dumping its stake in GlaxoSmithKline plc (LON: GSK), there’s still much to like about the share.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.


Berkshire Hathaway, the investment group of Warren Buffett, has just dumped its $19m stake in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

The amount was relatively small (for comparison, the group has a $16bn stake in Coca-Cola) and therefore was likely the move of a portfolio manager rather than Buffett himself.

Nonetheless, let’s see if we can assess the strategy behind it.

Why sell Glaxo?

The move represents a wider move away from healthcare stocks for Berkshire Hathaway. Recently the group has sold shares in Paris-based drug maker Sanofi and US pharmaceutical and consumer goods giant Johnson & Johnson.

For context: GlaxoSmithKline is the world’s fifth largest healthcare company and was established in 2000 after the merger of Glaxo Wellcome and SmithKline Beecham. It has a market cap of £81bn and the company’s three primary areas of business are pharmaceuticals, vaccines and consumer healthcare.

It has all the makings of a share that can form the bedrock of any portfolio. It’s defensive, meaning it provides a constant dividend and stable earnings, regardless of market volatility.

Glaxo also slowly appears to be returning to growth, with a rollout of new products set to offset competition from cheap, generic drugs. Last year the drugs maker had five new medicines approved by the FDA, and the pipeline should be further bolstered with reinvested capital from the sales of Lucozade and Ribena for $1.4bn.

The company projects 4% sales growth for 2014 and its scope to innovate is impressive. Based on the size and scale of the company alone Glaxo can afford to fully realise what begin as ideas and turn them in to successful products.

It offers a potential income of 4.5%, which beats the FTSE 100 average, to boot.

Why keep Glaxo?

There is potential for sizeable drug sales in emerging markets, and should current sales trends continue, total sales could eventually match the United States, the world’s largest market, by 2016. The shift in global drug spending is down to rising personal incomes, growing economies and health care reform. A push into emerging markets should pay off down the road for Glaxo.

Late last year the firm offered to spend £629m to increase its stake in its profitable Indian subsidiary to 75%, tapping into growing demand for medicines in the world’s second most populous country. 

We probably shouldn’t read too much into Berkshire’s motives, given the small size of the holding, so there’s no reason for investors to panic. If you thought GlaxoSmithKline looked like a good investment beforehand, stick with your instincts, and filter out any of the surrounding ‘noise’.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Mark doesn't own shares in any company mentioned. The Motley Fool recommends shares in GlaxoSmithKline.

More on Company Comment

Hand of person putting wood cube block with word VALUE on wooden table
Company Comment

Value has been building behind the Diageo share price

Despite the business growing, the Diageo share price first reached its current level just over 19 months ago and hasn't…

Read more »

Older couple walking in park
Investing Articles

5 stocks to buy for high and rising dividend income

I can see a host of shares to buy on the FTSE 100 offering me exceptional levels of income. Here…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I don’t care if FTSE 100 shares fall further, I’m buying them today

I'm happy to go shopping for FTSE 100 shares today, even though I accept that they could have further to…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Rolls-Royce shares are down 18% in a month and I’m finally going to buy them

Investors who bought Rolls-Royce shares have been repeatedly disappointed, but I'm willing to take a chance on them before they…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

How I’d invest £10k in a Stocks and Shares ISA today

Now looks like a good time to buy cheap FTSE 100 shares inside a Stocks and Shares ISA. These are…

Read more »

Black father holding daughter in a field of cows
Investing Articles

Today’s financial crisis is the perfect moment to buy cheap shares

I'm building a portfolio of FTSE 100 stocks by purchasing cheap shares whenever I see an opportunity. There's a good…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

I’d buy Tesco shares in October to bag their 5.4% yield 

Tesco shares have fallen lately but I think this makes them attractively valued for a dividend stock I would aim…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I would do anything to hold Diageo in my portfolio (but I won’t do that)

Diageo is one of my favourite stocks on the entire FTSE 100 and I'd love to hold it, but one…

Read more »